Articles On Cynata Therapeutics (ASX:CYP)

Title Source Codes Date
Cynata wins EU ethics approval for phase 2 Trial of CYP-001

Biotech company Cynata Therapeutics (ASX:CYP) received regulatory and ethics approval in the European Union (EU) for its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). CYP-001 is Cynata’s innovati...

themarketonline.com.au CYP 1 week ago
Closing Bell: ASX a little lower after hosting a Big 4 bank midweek spank

Local markets end lower on big bank sell-off Material gains offset by Telco’s and Financials  Small Caps led by rare earths developer Arafura   Local markets have not showered anyone in glory, profit or confidence on Thursday. At 4pm on T...

Stockhead CYP 2 weeks ago
Cynata Therapeutics’ breakthrough in regenerative medicine

  Peter Milios: I am Peter Milios from the Finance News Network, and today I am talking with Cynata Therapeutics. Cynata is a clinical stage stem cell and regenerative medicine company. Their ASX code is CYP and they have a market cap of ar...

ShareCafe CYP 2 weeks ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead CYP 3 weeks ago
Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment

Cynata Therapeutics’ (ASX:CYP) announces the enrolment and treatment of the first participant (CYP-001) in its Phase 2 clinical trial for high-risk acute graft versus host disease (aGvHD) US FDA has granted clearance for an Investigation...

themarketonline.com.au CYP 3 weeks ago
First Patient Treated in Phase 2 GvHD Trial

MELBOURNE, Australia, March 5, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enro...

FNArena CYP 3 weeks ago
ASX Health Stocks: Healius rips higher as new CEO takes over; Nova Eye bags record US sales

Healius has new CEO Nove Eye reports record US sales in February Cynata says first patient has been enrolled in Phase 2 trial   Healius has a new CEO, shares rip higher Healius (ASX:HLS) jumped 14% this morning after announcing that it wo...

Stockhead CYP 3 weeks ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead CYP 4 weeks ago
Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial

MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surfa...

FNArena CYP 1 month ago
ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns

Recce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the ASX!   Recce to expand diabetes foot ulcer Phase 1/2 trial An independent Safety Committee h...

Stockhead CYP 1 month ago
Closing Bell: ASX phones in more gains as prices plunge in Beijing and records tumble in New York

  ASX200 trims gains to end circa 0.3pc higher Sectors in the money include Utilities and IT Small cap winners led by Alliance Nickel and Sarytogan Graphite   A fresh batch of fat Q4 profit reports in the US overnight was apparently all t...

Stockhead CYP 1 month ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead CYP 4 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead CYP 5 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead CYP 6 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead CYP 6 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead CYP 6 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead CYP 6 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead CYP 7 months ago
ASX Health Stocks: Althea says its cannabis beverage could generate $5m of sales in Canada

Althea extends contract in Canada Clarity moves forward to cohort 3 Cynata opens Phase 2 recruitment   Althea extends deal in Canada for cannabis drinks Cannabis company Althea Group (ASX:AGH) announced that its wholly owned subsidiary, P...

Stockhead CYP 7 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead CYP 7 months ago
ASX Health Stocks: Medibio jumps 50pc on Phase 1 results; Cann doubles cannabis harvest

Medibio jumps after completing Phase 1 clinical trial Cann Group’s latest crop harvest is at a scale twice that of previous harvests 4DMedical wins a $1.1 million from the Fed government   Microcap Medibio (ASX:MEB) jumped 50% this mornin...

Stockhead CYP 8 months ago
Dr Boreham’s Crucible: Is this a case of what’s good for Mesoblast is good for Cynata?

The changing of the guard is not just evident at Buckingham Palace: barely a week goes by without an ASX-listed biotech announcing a new person at the helm. In the case of the junior stem-cell therapy developer Cynata (ASX:CYP), incumbent D...

Stockhead CYP 8 months ago
CLOSING BELL: Another red day on the ASX as Fed eyes ‘mild recession’ and big miners dip

S&P/ASX 200 closes well in the red today: -1.24% after US stocks dipped on the back of Fed hawkishness  Sectors-wise, IT was the only group finishing vaguely in the green, with Materials Discretionary and Financials stocks largely hamm...

Stockhead CYP 8 months ago
Cynata Therapeutics announces CEO succession and board changes

Australian clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Dr Kilian Kelly as its new CEO and managing director.

BiotechDispatch CYP 8 months ago
TMH Market Close: ASX200 closes the financial year in the green

The ASX200 closed the 2023 financial year marginally higher, ahead of significant Labor Government changes coming into effect from tomorrow. Workers on the minimum wage will be paid nearly six per cent more per hour, while employer’s sup...

themarketherald.com.au CYP 8 months ago
Cynata Therapeutics (AX:CYP) announces CEO succession and board changes

Cynata Therapeutics (CYP) appoints Dr Kilian Kelly as its CEO and Managing Director, effective July 1 Dr Kelly has held the role of CYP Chief Operating Officer since May 2019 and has been “instrumental” in advancing the company’s clinica...

themarketherald.com.au CYP 8 months ago
Cynata (ASX: CYP) appoints Dr Kilian Kelly as CEO & MD, welcomes Dr David Atkins to Board

Highlights Dr Kilian Kelly has been appointed to the position of Cynata’s Chief Executive Officer and Managing Director Dr Geoff Brooke, Chairman of the ASX-listed entity, commented that Dr Kelly's appointment reflects the "exciting gr...

Kalkine Media CYP 8 months ago
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead CYP 9 months ago
CLOSING BELL: Can you guess which company we all gave $2.7bn to announced a record $2.5bn profit today?

The ASX closed out the day flat, thanks to a last-minute selling spree Qantas announces record profit but still won’t give us back the money we gave them during Covid Westar Resources won the Small Caps race, in spite of a 90-minute hobbli...

Stockhead CYP 10 months ago
Cynata Therapeutics (ASX: CYP) to present two-year clinical study data in SR-aGvHD at ISCT

Highlights Cynata will present two-year patient follow-up data from its Phase 1 clinical trial of CYP-001 in SR-aGvHD at ISCT. ISCT, a major international conference, will be attended by delegates from more than 50 countries. As per...

Kalkine Media CYP 10 months ago
CLOSING BELL: Welcome to the ASX, where our motto is ‘chin up, mate… it could’ve been worse’

‘More of the same’ since lunchtime saw the benchmark land at -0.25% for the day Health Care coughed up a 1.09% lift while Financials weighed heavily on -0.71% Magnum Mining wins the Small Caps trophy with +44.1% thanks to Mitsubishi deal...

Stockhead CYP 10 months ago
Cynata Therapeutics (ASX:CYP) share purchase plan oversubscribed, funds to aid upcoming clinical trial

Highlights Together with the placement of AU$5 million, Cynata has been able to raise total proceeds of AU$7 million Valid applications were received by CYP for AU$2.05 worth of new shares under SPP, meaning oversubscription by ~AU$0.0...

Kalkine Media CYP 10 months ago
Cynata (ASX: CYP) reports positive initial data from clinical trial of CYP-006TK in DFUs

Highlights Cynata is testing the safety and efficacy of CYP-006TK in diabetic foot ulcers (DFUs), also called diabetic wounds, in an ongoing clinical trial Initial data from the first six patients is encouraging, demonstrating a notabl...

Kalkine Media CYP 10 months ago
ASX April Winners: Mid and small caps outperform blue-chip peers as gold stocks keep up rally

The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru...

Stockhead CYP 10 months ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead CYP 10 months ago
Cynata receives ethics approval for proposed aGvHD Phase 2 clinical trial

Clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has received approval from the Australian Human Research Ethics Committee to commence the proposed Phase 2 clinical trial in acute graft-versus-host disease.

BiotechDispatch CYP 11 months ago
ASX Health Stocks: Pharmaxis and Aroa lift on FDA news, Cynata to commence Phase 2 trial

Pharmaxis widens clinical trial following FDA guidance Aroa receives US FDA 510K clearance Cynata gets Australian Ethics approval to commence Phase 2   Pharmaxis to widen Phase 2 trial after FDA feedback Fibrotic diseases specialist Pharm...

Stockhead CYP 11 months ago
Cynata (ASX: CYP) gets Ethics green light to commence aGvHD Phase 2 clinical trial

Highlights Cynata previously received green light from the US FDA (Investigational New Drug application) The company also holds the Orphan Drug Status in the US for CYP-001, its lead product candidate Dr Jolanta Airey, Cynata’s Chief...

Kalkine Media CYP 11 months ago
Cynata Therapeutics (ASX: CYP) informs about capital raising of approximately AU$7 million

Highlights The placement of New Shares of Cynata Therapeutics is at the Offer Price of AU$0.215 per New Share The Share Purchase Plan would be available to eligible Cynata shareholders for up to AU$30,000 There is also one free attach...

Kalkine Media CYP 11 months ago
Top 10 at 10: Western Mines up 315% in two days as good news keeps flowing

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead CYP 11 months ago
Closing Bell: RBA Board finally bottles out, snapping its 10-month winning streak

The ASX jumped 0.3% after lunch as the RBA finally kept rates on hold. XGD All Ordinaries Gold soared ~3.0% because someone missed a memo. Besra Gold is back on top with a 36% leap after Quantum’s cheque cleared customs.   Local markets w...

Stockhead CYP 11 months ago
Cynata’s (ASX:CYP) DFU clinical trial makes progress with addition of three sites

Highlights Cynata Therapeutics has added three new sites to the ongoing clinical trial of its compound CYP-006TK. The study targets to enrol 30 patients affected by diabetic foot ulcers (DFU). With this latest development, the company...

Kalkine Media CYP 1 year ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead CYP 1 year ago
Cynata receives IRB approval for proposed phase 2 aGvHD clinical trial

Cell therapy company Cynata Therapeutics (ASX:CYP) has received approval to commence the proposed phase 2 clinical trial in acute graft-versus-host disease.

BiotechDispatch CYP 1 year ago
Cynata Therapeutics (ASX:CYP) receives approval for acute graft-versus-host disease clinical trial

Cynata Therapeutics (CYP) receives approval to launch a phase two clinical trial in acute graft-versus-host disease The clinical stage biotech company was granted the green light to undertake the trial from Advarra, a central institution...

themarketherald.com.au CYP 1 year ago
Cynata’s (ASX:CYP) proposed aGvHD phase 2 clinical trial gets IRB approval

Highlights Cynata has secured approval to start the proposed aGvHD phase 2 clinical trial in the US. The approval was granted by Advarra, Inc., a central Institutional Research Board (IRB) service provider in the USA. IRB approval is...

Kalkine Media CYP 1 year ago
Which ASX stocks are on the path from FDA to clinical trial in 2023?

Cynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biotechs need to do to commence a clinical trial Which ASX biotechs have an IND submission to the FDA and will start a clinical trial soon?   Wh...

Stockhead CYP 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead CYP 1 year ago
Cynata (ASX:CYP) strengthens its IP position with new Australian patent

Highlights Cynata has received a Notice of Acceptance from IP Australia for a patent describing a component of its Cymerus™ MSC platform technology. The patent further bolsters the current broad and inclusive IP protection of the Cymer...

Kalkine Media CYP 1 year ago
How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead CYP 1 year ago